Literature DB >> 21777949

Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.

Thomas K Lee1, Alcides Chaux, Sarah Karram, Hiroshi Miyamoto, Jeremy S Miller, Daniel A Fajardo, Jonathan I Epstein, George J Netto.   

Abstract

Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.

Entities:  

Mesh:

Year:  2011        PMID: 21777949     DOI: 10.1016/j.humpath.2011.03.006

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Bladder papillary urothelial neoplasm of low malignant potential in Chinese: a clinical and pathological analysis.

Authors:  Xin-Ke Zhang; Ying-Ying Wang; Jie-Wei Chen; Tao Qin
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium.

Authors:  Dimitra P Vageli; Stavros Giannopoulos; Sotirios G Doukas; Christos Kalaitzis; Stilianos Giannakopoulos; Alexandra Giatromanolaki; George K Koukoulis; Stavros Touloupidis
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

3.  Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.

Authors:  Jay P Maxwell; Cheng Wang; Nicholas Wiebe; Asli Yilmaz; Kiril Trpkov
Journal:  Diagn Pathol       Date:  2015-03-13       Impact factor: 2.644

4.  Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT: Comparative Analyses with Noninvasive Low-Grade Papillary Urothelial Carcinoma (LGPUC).

Authors:  Jung Kwon Kim; Kyung Chul Moon; Chang Wook Jeong; Cheol Kwak; Hyun Hoe Kim; Ja Hyeon Ku
Journal:  J Cancer       Date:  2017-08-24       Impact factor: 4.207

Review 5.  Urothelial bladder tumour in childhood: A report of two cases and a review.

Authors:  Usama N Rifat; Nader Y Hamadalla; Khalid C Chiad Safi; Salwan S Al Habash; Mustafa Mohammed
Journal:  Arab J Urol       Date:  2014-11-26

6.  Downregulation of miR-133b predict progression and poor prognosis in patients with urothelial carcinoma of bladder.

Authors:  Xiaonan Chen; Bin Wu; Zhenqun Xu; Shijie Li; Shutao Tan; Xuefeng Liu; Kefeng Wang
Journal:  Cancer Med       Date:  2016-06-12       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.